

TRANSMITTAL FORM



IFW

Application Serial Number	10/714,165
Filing Date	November 14, 2003
First Named Inventor	Gillies
Group Art Unit	1641
Examiner Name	Not Yet Assigned
Attorney Docket No.	LEX-004C1
Confirmation No.	2258

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form <input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____] <input type="checkbox"/> Petition for Extension of Time <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (2 pages) <input checked="" type="checkbox"/> Form PTO-1449 (10 pgs.) <input checked="" type="checkbox"/> Copies of IDS Citations (B108-B173 and C262-C319) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <input type="checkbox"/> Power of Attorney By Assignee of Entire Interest/Revocation of Prior Powers and New Power of Attorney <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> CD(s) for large table or computer program <input type="checkbox"/> Amendment After Allowance <input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate)	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Brief (in triplicate) <input type="checkbox"/> Status Inquiry <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 <input type="checkbox"/> Additional Enclosure(s) (please identify below)
---	--	--

CORRESPONDENCE ADDRESS

Direct all correspondence to:
 Patent Administrator
 Kirkpatrick & Lockhart Nicholson
 Graham LLP
 75 State Street
 Boston, MA 02109-1808
 Tel. No.: (617) 261-3100
 Fax No.: (617) 261-3175

SIGNATURE BLOCK

Respectfully submitted,

Brian A. Fairchild
 Attorney for Applicant
 Kirkpatrick & Lockhart Nicholson
 Graham LLP
 75 State Street
 Boston, MA 02109-1808

Date: July 18, 2005
 Reg. No. 48,645
 Tel. No.: (617) 261-3169
 Fax No.: (617) 261-3175



PATENT
Attorney Docket No. LEX-004C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies CONFIRMATION NO.: 2258
SERIAL NO.: 10/714,165 GROUP NO.: 1641
FILING DATE: November 14, 2003 EXAMINER: Not yet assigned
TITLE: IL-15 Immunoconjugates and Uses Thereof

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non-U.S. patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) above but before the mailing date of any of a **final action** under 37 C.F.R. 1.113, a **notice of allowance** under 37 C.F.R. 1.311, or an action that otherwise closes prosecution in the application, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein; or


- ☐ (3) after the period defined in (2) above but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Date: July 18, 2005
Reg. No. 48,645

Tel. No.: (617) 261-3169
Fax No.: (617) 261-3175

Respectfully submitted,



Brian A. Fairchild
Attorney for Applicant
Kirkpatrick & Lockhart Nicholson
Graham LLP
75 State Street
Boston, Massachusetts 02109-1808



FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: LEX-004C1 APPLICANT(S): Gillies SERIAL NO.: 10/714,165 CONF. NO.: 2258 FILING DATE: November 14, 2003 GROUP: 1641			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A111	4,469,797	9/4/84	Albarella			
	A112	4,816,567	3/28/89	Cabilly <i>et al.</i>			
	A113	4,946,778	8/7/90	Ladner <i>et al.</i>			
	A114	4,975,369	12/4/90	Beavers <i>et al.</i>			
	A115	5,019,368	5/28/91	Epstein <i>et al.</i>			
	A116	5,225,539	7/6/93	Winter			
	A117	5,349,053	9/20/94	Landolfi			
	A118	5,480,981	1/2/96	Goodwin <i>et al.</i>			
	A119	5,585,089	12/17/96	Queen <i>et al.</i>			
	A120	5,609,846	3/11/97	Goldenberg			
	A121	5,614,184	3/25/97	Sytkowski <i>et al.</i>			
	A122	5,650,150	7/22/97	Gillies			
	A123	5,679,543	10/21/97	Lawlis			
	A124	5,709,859	1/20/98	Aruffo <i>et al.</i>			
	A125	5,712,120	1/27/98	Rodriguez <i>et al.</i>			
	A126	5,723,125	3/3/98	Chang <i>et al.</i>			
	A127	5,726,044	3/10/98	Lo <i>et al.</i>			
	A128	5,728,552	3/17/98	Fujisawa <i>et al.</i>			
	A129	5,770,195	6/23/98	Hudziak <i>et al.</i>			
	A130	5,807,715	9/15/98	Morrison <i>et al.</i>			
	A131	5,827,516	10/27/98	Urban <i>et al.</i>			
	A132	5,827,703	10/27/98	Debs <i>et al.</i>			
	A133	5,837,821	11/17/98	Wu <i>et al.</i>			
	A134	5,843,423	12/1/98	Lyman <i>et al.</i>			
	A135	5,888,773	3/30/99	Jost <i>et al.</i>			
	A136	5,908,626	6/1/99	Chang <i>et al.</i>			
EXAMINER				DATE CONSIDERED			

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-004C1			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies			
				SERIAL NO.: 10/714,165 CONF. NO.: 2258			
				FILING DATE: November 14, 2003 GROUP: 1641			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A137	6,086,875	7/11/00	Blumberg <i>et al.</i>			
	A138	6,100,387	8/8/00	Herrmann <i>et al.</i>			
	A139	6,169,070	1/2/01	Chen <i>et al.</i>			
	A140	6,291,158	9/18/01	Winter <i>et al.</i>			
	A141	6,335,176	1/1/02	Inglese <i>et al.</i>			
	A142	6,335,176	01/01/02	Inglese <i>et al.</i>			
	A143	6,444,792	9/3/02	Gray <i>et al.</i>			
	A144	6,475,717	11/5/02	Enssle <i>et al.</i>			
	A145	6,485,726	11/26/02	Blumberg <i>et al.</i>			
	A146	6,500,641	12/31/02	Chen <i>et al.</i>			
	A147	6,551,592	4/22/03	Lindhofer <i>et al.</i>			
	A148	6,617,135	9/9/03	Gillies <i>et al.</i>			
	A149	6,620,413	09/16/03	DeSavage <i>et al.</i>			
	A150	6,627,615	9/30/03	Debs <i>et al.</i>			
	A151	6,646,113	11/11/03	Dreyfuss <i>et al.</i>			
	A152	6,750,329	6/15/04	Rosenblum <i>et al.</i>			
	A153	6,838,260	01/04/05	Gillies <i>et al.</i>			
	A154	2003/0105294	6/5/03	Gillies <i>et al.</i>			
	A155	2003/0139365	7/24/03	Lo <i>et al.</i>			
	A156	2003/0139575	7/24/03	Gillies			
	A157	2003/0157054	8/21/03	Gillies <i>et al.</i>			
	A158	2003/0166163	9/4/03	Gillies			
	A159	2003/0166877	9/4/03	Gillies <i>et al.</i>			
	A160	2004/0033210	2/19/04	Gillies			
	A161	2004/0043457	3/4/04	Schumacher <i>et al.</i>			
	A162	2004/0053366	3/18/04	Lo <i>et al.</i>			
EXAMINER				DATE CONSIDERED			

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: LEX-004C1 APPLICANT(S): Gillies SERIAL NO.: 10/714,165 CONF. NO.: 2258 FILING DATE: November 14, 2003 GROUP: 1641			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A163	2004/0072299	4/15/04	Gillies <i>et al.</i>			
	A164	2004/0082039	4/29/04	Gillies <i>et al.</i>			
	A165	2004/0180386	9/16/04	Carr <i>et al.</i>			
	A166	2004/0203100	10/14/04	Gillies <i>et al.</i>			
	A167	2005/0069521	03/31/05	Gillies <i>et al.</i>			

EXAMINER	DATE CONSIDERED
----------	-----------------

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-004C1					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies					
				SERIAL NO.: 10/714,165 CONF. NO.: 2258					
				FILING DATE: November 14, 2003 GROUP: 1641					
FOREIGN PATENT DOCUMENTS									
EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B108	0 294 703 A2	12/14/88	EP					Y
	B109	0 308 936 B1	3/29/89	EP					Y
	B110	0 314 317 B1	5/3/89	EP					Y
	B111	0 318 554 B1	6/7/89	EP					Y
	B112	0 326 120 B1	8/2/89	EP					Y
	B113	0 344 134 B1	01/19/94	EP					Y
	B114	0 350 230 A2	1/10/90	EP					Y
	B115	0 375 562 B1	6/27/90	EP					Y
	B116	0 396 387 A2	11/7/90	EP					Y
	B117	0 428 596 B1	4/17/96	EP					Y
	B118	0 439 095 A2	7/31/91	EP					Y
	B119	0 511 747 A1	11/4/92	EP					Y
	B120	0 519 596 A1	13/32/92	EP					Y
	B121	0 601 043 B1	6/15/94	EP					Y
	B122	0 699 755 A2	3/6/96	EP					Y
	B123	0 706 799 A2	4/17/96	EP					Y
	B124	1 088 888 A1	4/4/01	EP					Y
	B125	21725/88	3/23/89	AU					Y
	B126	2 188 638	10/7/87	GB					Y
	B127	WO 86/01533	3/13/86	PCT					Y
	B128	WO 88/00052	1/14/88	PCT					Y
	B129	WO 88/09344	12/1/88	PCT					Y

EXAMINER	DATE CONSIDERED
-----------------	------------------------

FORM PTO - 1449					ATTORNEY DOCKET NO.: LEX-004C1				
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT					APPLICANT(S): Gillies				
					SERIAL NO.: 10/714,165 CONF. NO.: 2258				
					FILING DATE: November 14, 2003 GROUP: 1641				
FOREIGN PATENT DOCUMENTS									
EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B130	WO 89/02922	4/6/89	PCT					Y
	B131	WO 89/09620	10/19/89	PCT				Y	Y
	B132	WO 91/00360	1/10/91	PCT					Y
	B133	WO 91/04329	04/04/91	PCT					Y
	B134	WO 91/08298	6/13/91	PCT					Y
	B135	WO 91/13166	9/5/91	PCT					Y
	B136	WO 91/14438	10/3/91	PCT					Y
	B137	WO 92/02240	2/20/92	PCT					Y
	B138	WO 92/08495	5/29/92	PCT					Y
	B139	WO 92/08801	5/29/92	PCT					Y
	B140	WO 92/10755	6/25/92	PCT					Y
	B141	WO 92/16562	10/1/92	PCT					Y
	B142	WO 93/03157	2/18/93	PCT					Y
	B143	WO 94/25609	11/10/94	PCT					Y
	B144	WO 95/05468	2/23/95	PCT					Y
	B145	WO 95/21258	8/10/95	PCT					Y
	B146	WO 95/31483	11/23/95	PCT					Y
	B147	WO 96/04388	02/15/96	PCT					Y
	B148	WO 96/08570	3/21/96	PCT					Y
	B149	WO 96/18412	6/20/96	PCT					Y
	B150	WO 96/40792	12/19/96	PCT					Y
	B151	WO 97/00317	1/3/97	PCT					Y
	B152	WO 97/00319	1/3/97	PCT					Y

EXAMINER	DATE CONSIDERED
-----------------	------------------------

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-004C1					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies					
				SERIAL NO.: 10/714,165 CONF. NO.: 2258					
				FILING DATE: November 14, 2003 GROUP: 1641					
FOREIGN PATENT DOCUMENTS									
EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B153	WO 97/24137	7/10/97	PCT					Y
	B154	WO 97/24440	7/10/97	PCT					Y
	B155	WO 97/30089	8/21/97	PCT					Y
	B156	WO 97/33617	9/18/97	PCT					Y
	B157	WO 97/33619	9/18/97	PCT					Y
	B158	WO 97/34631	9/25/97	PCT					Y
	B159	WO 97/43316	11/20/97	PCT					Y
	B160	WO 98/00127	1/8/98	PCT					Y
	B161	WO 98/28427	7/2/98	PCT					Y
	B162	WO 98/30706	7/16/98	PCT					Y
	B163	WO 98/46257	10/22/98	PCT					Y
	B164	WO 98/52976	11/26/98	PCT					Y
	B165	WO 98/59244	12/30/98	PCT					Y
	B166	WO 99/02709	01/21/99	PCT					Y
	B167	WO 99/03887	01/28/99	PCT					Y
	B168	WO 99/29732	6/17/99	PCT					Y
	B169	WO 99/43713	9/2/99	PCT					Y
	B170	WO 99/52562	10/21/99	PCT					Y
	B171	WO 00/01822	1/13/00	PCT					Y
	B172	WO 00/34317	06/15/00	PCT					Y
	B173	WO 02/079232	10/10/02	PCT					Y

EXAMINER	DATE CONSIDERED
-----------------	------------------------

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-004C1
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies
		SERIAL NO.: 10/714,165 CONF. NO.: 2258
		FILING DATE: November 14, 2003 GROUP: 1641
OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C262	Adkins et al., (1998), "Edrecolomab (Monoclonal Antibody 17-1A)," Drugs, 56(4):619-626.
	C263	Anderson et al., (1980), "Characterization of the Fc Receptor for IgG on a Human Macrophage Cell Line U937," J. Immunol., 125(6):2735-41.
	C264	Baici et al., (1980), "Kinetics of the Different Susceptibilities of the Four Human Immunoglobulin G Subclasses to Proteolysis by Human Lysosomal Elastase," Scand. J. Immunol. 12(1):41-50.
	C265	Boulianne et al., (1984), "Production of Functional Chimaeric Mouse/Human Antibody," Nature, 312:643-6.
	C266	Bourgois et al., (1974), "Determination of the Primary Structure of a Mouse IgG2a Immunoglobulin: Amino-Acid Sequence of the Fc Fragment: Implications for the Evolution of Immunoglobulin Structure and Function," Eur. J. Biochem., 43:423-35.
	C267	Brambell et al., (1964), "A Theoretical Model of γ -Globulin Catabolism," Nature, 203:1352-55.
	C268	Brekke et al., (1994), "Human IgG Isotype-Specific Amino Acid Residues Affecting Complement-Mediated Cell Lysis and Phagocytosis," Eur. J. Immunol., 24:2542-2547.
	C269	Bubenik et al., (1995), "Interleukin-2 Gene Therapy of Residual EL-4 Leukaemia Potentiates the Effect of Cyclophosphamide Pretreatment," J. Cancer Res. Clin. Oncol., 121:39-43.
	C270	Chan et al., (1992), "Mechanisms of IFN- γ Induction by Natural Killer Cell Stimulatory Factor (NKSF/IL-12). Role of Transcription and mRNA Stability in the Synergistic Interaction Between NKSF and IL-2," J. Immunol., 148:92-98.
	C271	Chappel et al., (1991), "Identification of the Fc Gamma Receptor Class I Binding Site In Human IgG Through Use of Recombinant IgG1/IgG2 Hybrid and Point-Mutated Antibodies," Proc. Natl. Acad. Sci. USA, 88(20):9036-40.
	C272	Cirulli et al., (1998), "KSA Antigen Ep-CAM Mediates Cell-Cell Adhesion of Pancreatic Epithelial Cells: Morphoregulatory Roles in Pancreatic Islet Development," J. Cell Biol., 140:1519-34.
	C273	Cohen et al., (1998), "An Artificial Cell-Cycle Inhibitor Isolated from a Combinatorial Library," Proc. Natl. Acad. Sci. USA, 95:14272-7.
	C274	Ellison et al., (1982), "The Nucleotide Sequence of a Human Immunoglobulin C γ 1 Gene," Nucleic Acids Res., 10:4071-9.
	C275	Ghetie et al., (1997), "FcRn: The MHC Class I-Related Receptor that is More Than an IgG Transporter," Immunology Today, 18(12):592-598.

EXAMINER	DATE CONSIDERED
-----------------	------------------------

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-004C1 APPLICANT(S): Gillies SERIAL NO.: 10/714,165 CONF. NO.: 2258 FILING DATE: November 14, 2003 GROUP: 1641	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C276	Gurewich et al., (1988), "Characterization of the Intrinsic Fibrinolytic Properties of Pro-Urokinase Through a Study of Plasmin-Resistant Mutant Forms Produced by Site-Specific Mutagenesis of Lysine," J. Clin. Invest., 82:1956-1962.	
	C277	Hornick et al., (1999), "Pretreatment with a Monoclonal Antibody/Interleukin-2 Fusion Protein Directed Against DNA Enhances the Delivery of Therapeutic Molecules to Solid Tumors," Clin. Cancer Research, 5:51-60.	
	C278	Hulett et al., (1994), "Molecular Basis of Fc Receptor Function," Adv. Immunol., 57:1127.	
	C279	Hurn et al., (1980), "Production of Reagent Antibodies," Methods in Enzymology, 70: 104-142.	
	C280	Huston et al., (1988), "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced In Escherichia Coli," Proc. Natl. Acad. Sci. USA, 85:5879-5883.	
	C281	Isaacs et al., (1998), "Therapy with Monoclonal Antibodies. II. The Contribution of Fcγ Receptor Binding and the Influence of CH1 and CH3 Domains on In Vivo Effector Function," J. Immunol., 161:3862-3869.	
	C282	Jefferis et al., (1990), "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors huFcγR," Mol. Immunol., 27(12):1237-1240.	
	C283	Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenized with Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7.	
	C284	MacLean et al., (1996), "Enhancing the Effect of Theratope STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide," J. Immunother., 19(4):309-316.	
	C285	Mariani et al., (1997), "Tumor Targeting Potential of the Monoclonal Antibody BC-1 against Oncofetal Fibronectin in Nude Mice Bearing Human Tumor Implants," Cancer, 80:2378-84.	
	C286	Martin et al., (2001), "Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding," Mol. Cell., 7(4):867-77.	
	C287	Mateo et al., (2000), "Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity," Hybridoma, 19(6):463-471.	
	C288	McMahan et al., (1991), "A Novel IL-1 Receptor, Cloned From B-Cells by Mammalian Expression is Expressed in Many Cell Types," EMBO J., 10:2821-32.	
	C289	Menard et al., (1983), "Generation of Monoclonal Antibodies Reacting with Normal and Cancer Cells of Human Breast," Cancer Res., 43:1295-300.	
	C290	Miyake et al., (1988), "Synthesis of Recombinant Human Single-Chain Urokinase-Type Plasminogen Activator Variants Resistant to Plasmin and Thrombin," J. Biochem., 104:643-647.	
EXAMINER		DATE CONSIDERED	

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-004C1
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies
		SERIAL NO.: 10/714,165 CONF. NO.: 2258
		FILING DATE: November 14, 2003 GROUP: 1641
OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C291	Morrison et al., (1984), "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains," Proc. Natl. Acad. Sci. USA, 81:6851-5.
	C292	Nastala et al., (1994), "Recombinant IL-12 Administration Induces Tumor Regression in Association with IFN- γ Production," J. Immunol., 153:1697-706.
	C293	Neal et al., (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-Dependent Immunotherapy," Cancer Immunol. Immunother., 53:41-52.
	C294	Nelles et al., (1987), "Characterization of Recombinant Human Single Chain Urokinase-Type Plasminogen Activator Mutants Produced by Site-Specific Mutagenesis of Lysine 158," J. Biol. Chem., 262(12):5682-5689.
	C295	Orlandi et al., (1989), "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction," Proc. Natl. Acad. Sci. USA, 86:3833-7.
	C296	Pedley et al. (1999), "Enhancement of Antibody-Directed Enzyme Prodrug Therapy in Colorectal Xenografts by an Antivascular Agent," Cancer Res., 59:3998-4003.
	C297	Poon et al., (1995), "Structure and Function of Several Anti-Dansyl Chimeric Antibodies Formed by Domain Interchanges Between Human IgM and Mouse IgG2b," J. Biol. Chem., 270:8571-7.
	C298	Queen et al., (1989), "A Humanized Antibody that Binds to the Interleukin 2 Receptor," Proc. Natl. Acad. Sci. USA, 86:10029-33.
	C299	Riechmann et al., (1988), "Reshaping Human Antibodies for Therapy," Nature, 332:323-7.
	C300	Robinson et al., (1998), "Optimizing the Stability of Single-Chain Proteins by Linker Length and Composition Mutagenesis," Proc. Natl. Acad. Sci. USA, 95:5929-34.
	C301	Sakano et al., (1980), "Two Types of Somatic Recombination are Necessary for the Generation of Complete Immunoglobulin Heavy-Chain Genes," Nature, 286:676-683.
	C302	Schwartzberg et al., (2001), "Clinical Experience with Edrecolomab: A Monoclonal Antibody Therapy for Colon Carcinoma," Critical Reviews in Oncology/Hematology, 40:17-24.
	C303	Senior et al., (2000), "Cleavage of a Recombinant Human Immunoglobulin A2 (IgA2)-IgA1 Hybrid Antibody by Certain Bacterial IgA1 Proteases," Infect. Immun., 68(2):463-9.
	C304	Sharp et al., (1988), "Codon Usage Patterns in Escherichia coli, Bacillus subtilis, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Drosophila melanogaster and Homo sapiens; a Review of the Considerable Within-Species Diversity," Nucleic Acids Res., 16(17):8207-8211.
	C305	Takai, (2002), "Roles of Fc Receptors in Autoimmunity," Nat. Rev. Immunol., 2(8):580-92.

EXAMINER	DATE CONSIDERED
----------	-----------------

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-004C1
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies
		SERIAL NO.: 10/714,165 CONF. NO.: 2258
		FILING DATE: November 14, 2003 GROUP: 1641
OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C306	Tiruppathi et al., (1996), "Isolation and Characterization of a Cell Surface Albumin-Binding Protein from Vascular Endothelial Cells," Proc. Nat. Acad. Sci. USA, 93:250-4.
	C307	Voest et al., (1995), "Inhibition of Angiogenesis in Vivo by Interleukin 12," J. Natl. Canc. Inst., 87:581-6.
	C308	Ward et al., (1995), "The Effector Functions of Immunoglobulins: Implications for Therapy," Therapeutic Immunology, 2:77-94.
	C309	Weber et al., (2001), "Phase I Trial of huKS-IL2 Immunocytokine in Patients with Prostate Carcinoma: Clinical, PK, and Biological PD Results (Abstract)," American Society of Clinical Oncology Program/Proceedings, 20(Part 1):259a.
	C310	Weitkamp et al., (1973), "Additional Data on the Population Distribution of Human Serum Albumin Genes; Three New Variants," Ann. Hum. Genet., 37:219-26.
	C311	Wells, (1990), "Additivity of Mutational Effect in Proteins," Biochemistry, 29(37):8509-8517.
	C312	Woof et al., (1986), "Localisation of the Monocyte-Binding Region on Human Immunoglobulin G," Mol. Immunol., 23:319-30.
	C313	Wysocka et al., (1995), "Interleukin-12 is Required for Interferon- γ Production and Lethality in Lipopolysaccharide-Induced Shock in Mice," Eur. J. Immunol., 25:672-6.
	C314	Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," J. Biol. Chem., 269(5):3469-3474.
	C315	Yan et al., (1996), "Characterization of an Ig VH Idiotope that Results in Specific Homophilic Binding and Increased Avidity for Antigen," J. Immunol., 157:1582-8.
	C316	Yeh et al., (1992), "Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate," Proc. Natl. Acad. Sci. USA, 89:1904-8.
	C317	Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," J. Clinical Oncology, 16(6):2169-80.
	C318	Zhu et al., (2001), "MHC Class I-Related Neonatal Fc Receptor for IgG is Functionally Expressed in Monocytes, Intestinal Macrophages and Dendritic Cells," J. Immunol., 166:3266-3276.
	C319	Zuckier et al., (1998), "Chimeric Human-Mouse IgG Antibodies with Shuffled Constant Region Exons Demonstrate that Multiple Domains Contribute to In Vivo Half-Life," Cancer Res., 58(17):3905-8.

BOS-875135 v1

EXAMINER	DATE CONSIDERED
-----------------	------------------------